John Mendlein, Ph.D., J.D.
Executive Partner, Flagship Pioneering
Dr. Mendlein joined Flagship Pioneering as Executive Partner in February 2019. A longtime member of Flagship’s broader ecosystem of companies, Dr. Mendlein is an experienced biotech leader and has served in numerous executive and board roles. He contributes to Flagship’s strategic and operational objectives, including the origination of new Flagship Labs companies, serves on the boards of Flagship’s companies, and works with portfolio company CEOs and their teams to achieve the best attainable value for each organization.
Prior to joining Flagship, Dr. Mendlein served as President of Corporate and Product Strategy at Moderna Therapeutics. He led the cross-functional team responsible for ensuring Moderna’s readiness for its initial public offering in 2018, and was a member of its board of directors from 2012-2018.
During his career, Dr. Mendlein has served as Chief Knowledge Officer, General Counsel, and board member at Aurora Biosciences; CEO of Adnexus Therapeutics; Executive Chairman, Founder, and Interim CEO of Fate Therapeutics; and Executive Chairman and CEO of Affinium Pharmaceuticals. He is a founder and board member of Homes for Sudan, a non-profit in Boston, MA, and a scientific advisory board member for Ocean Discovery Institute, a non-profit in San Diego, CA. He has served on the boards of the Biotechnology Innovation Organization, as well as on three of Flagship’s companies: Moderna, Axcella Health and Editas Medicine.
Dr. Mendlein holds a Ph.D. in Physiology and Biophysics from the University of California, Los Angeles, a J.D. from the University of California, Hastings College of the Law, and a B.S. in Biology from the University of Miami.